Tag Archives: Ovid Therapeutics Inc

Cowen & Co. Thinks Ovid Therapeutics Inc’s Stock is Going to Recover

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Ovid Therapeutics Inc (OVID – Research Report) today. The company’s shares opened today at $2.31, close to its 52-week low of $1.53. According to TipRanks.com, Baral is a top

Ovid Therapeutics Inc (OVID) Gets a Buy Rating from Ladenburg

In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Ovid Therapeutics Inc (OVID – Research Report), with a price target of $27. The company’s shares opened today at $1.73, close to its 52-week low of

Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ovid Therapeutics Inc (OVID – Research Report). The company’s shares closed on Friday at $1.71, close to its 52-week low of $1.64. According to

Cantor Fitzgerald Sticks to Their Buy Rating for Ovid Therapeutics Inc (OVID)

Cantor Fitzgerald analyst Charles Duncan reiterated a Buy rating on Ovid Therapeutics Inc (OVID – Research Report) today and set a price target of $10. The company’s shares opened today at $3.47, close to its 52-week low of $3.22. Duncan

Cowen & Co. Reaffirms Their Buy Rating on Ovid Therapeutics Inc

Cowen & Co. analyst Eric Schmidt maintained a Buy rating on Ovid Therapeutics Inc (NASDAQ: OVID) yesterday. The company’s shares closed on Thursday at $7.07. According to TipRanks.com, Schmidt is a top 25 analyst with an average return of 42.6%